Evidence map›Paper›PMID 26918465›Full record

ArticleHuman gene therapy methods2016

Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene.

Amy H Lin, Yanzheng Liu, Cynthia Burrascano, Kathrina Cunanan, Christopher R Logg, Joan M Robbins, Noriyuki Kasahara, Harry Gruber, Carlos Ibañez, Douglas J Jolly

Open access · greenAbstract read
In one paragraph

Article in Human gene therapy methods, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Amy H Lin1 Tocagen Inc. , San Diego, California.
Yanzheng Liu1 Tocagen Inc. , San Diego, California.
Cynthia Burrascano1 Tocagen Inc. , San Diego, California.
Kathrina Cunanan1 Tocagen Inc. , San Diego, California.
Christopher R Logg2 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles , Los Angeles, California.
Joan M Robbins1 Tocagen Inc. , San Diego, California.
Noriyuki Kasahara2 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles , Los Angeles, California.
Harry Gruber1 Tocagen Inc. , San Diego, California.
Carlos Ibañez1 Tocagen Inc. , San Diego, California.
Douglas J Jolly1 Tocagen Inc. , San Diego, California.
Retriev Technologies (United States) · USUniversity of California, Los Angeles · USUniversity of Miami · US

Funding

Translational Development of Replication-Competent Retrovirus VectorsU01NS059821 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KASAHARA, NORIYUKI · 2010 to 2013
$2.9M
Combining Virotherapy and Immunotherapy for CancerR01CA105171 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KASAHARA, NORIYUKI · 2004 to 2008
$1.5M
NCI NIH HHS R01-CA105171NINDS NIH HHS U01-NS59821
6 · The paper itself

Abstract

We have developed retroviral replicating vectors (RRV) derived from Moloney murine gammaretrovirus with an amphotropic envelope and an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES)-transgene cassette downstream of the env gene. During long-term (180 days) replication of the vector in animals, a bulge of 7 adenosine residues (A's) in the J-K bifurcation domain sometimes serially added A's. Therefore, vectors with 4-12 A's in the A bulge in the J-K bifurcation domain were generated, and the impact of the variants on transgene protein expression, vector stability, and IRES sequence upon multiple infection cycles was assessed in RRV encoding yeast-derived cytosine deaminase and green fluorescent protein in vitro. For transgene protein expression, after multiple infection cycles, RRV-IRES with 5-7 A's gave roughly comparable levels, 4 and 8 A's were within about 4-5-fold of the 6 A's, whereas 10 and 12 A's were marked lower. In terms of stability, after 10 infection cycles, expansion of A's appeared to be a more frequent event affecting transgene protein expression than viral genome deletions or rearrangement: 4 and 5 A's appeared completely stable; 6, 7, and particularly 8 A's showed some level of expansion in the A bulge; 10 and 12 A's underwent both expansion and transgene deletion. The strong relative translational activity of the 5 A's in the EMCV IRES has not been reported previously. The 5A RRV-IRES may have utility for preclinical and clinical applications where extended replication is required.

Indexed as

Genetic VectorsAnimalsCell Line, TumorCytosine DeaminaseEncephalomyocarditis virusFemaleGreen Fluorescent ProteinsHEK293 CellsHumansInternal Ribosome Entry SitesMice, Inbred BALB CMoloney murine leukemia virusProtein BiosynthesisRNA, ViralTransgenesCytosine DeaminaseGreen Fluorescent ProteinsInternal Ribosome Entry SitesRNA, Viral

Identifiers

PMID26918465
PMCPMC4834527
OpenAlexW2340623231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.